Michael Bishop, MD, MS

Research Program: Cancer Therapeutics Faculty Rank: Associate Professor Campus: Arkansas Children's Hospital College: College of Medicine Department: Peds Hematology

Cancer Research Interest

• Disease Site Focus: Pediatric Oncology, Sarcoma, Musculoskeletal
• Research Focus Area: Treatment, Diagnosis/ Prognosis
• Type of Research: Clinical
• Research Keywords: Osteosarcoma, tyrosine kinase inhibitors, Ewing sarcoma, Soft tissue sarcoma, Adolescent and young adult oncology
• Research Interest Statement: I am a clinical investigator primarily focused on identifying novel therapeutic approaches for the treatment of primary bone malignancies such as osteosarcoma. I am a member of the Bone Tumor Committee in the Children's Oncology Group and I am the Study Chair for the COG study AOST2032, a Phase 2/3 randomized study of the addition of the multi-targeted tyrosine kinase inhibitor cabozantinib to cytotoxic chemotherapy for patients with newly diagnosed osteosarcoma. My clinical interests align with efforts to improve overall medical and psychosocial care for adolescents and young adults with cancer who have unique needs that are often unmet by both pediatric and adult treatment settings and require dedicated programming to optimize their care and well-being. I additionally serve as the Associate Director for Clinical and Translational Research for the Arkansas Children's Research Institute where I work with ACRI team members and UAMS Department of Pediatrics faculty to identify opportunities to increase the number of clinical trials available to children and adolescents receiving medical care in Arkansas.

Contact Information

• Email Address: MBishop@uams.edu
• Profiles Research Networking Software: View Profile

Recent Publications

• Bishop MW. Osteosarcoma: Diagnosis, Treatment, and Emerging Opportunities. Hematology/oncology clinics of North America. 2025 39(4):749-760. PMID: 40368742.
• Sookdeo J, Wang L, Bishop MW, [et al.]. SMARCA4-deficient primary bone sarcoma with "teratoid" features in a rhabdoid tumor predisposition syndrome patient. Virchows Archiv : an international journal of pathology. 2025 486(3):611-616. PMID: 39112597.
• Cuthbert C, Zaghloul T, Bhatia S, [et al., including Bishop MW]. Use of Vacuum-Assisted Closure to Reduce the Likelihood of Wound Complications After Limb-Sparing Resection of Pediatric Primary Bone Sarcomas of the Femur. Journal of pediatric surgery. 2024 59(9):1735-1739. PMID: 38548494.
• Duncan C, Sarvode Mothi S, Santiago TC, [et al., including Bishop MW]. Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment. Journal of the National Cancer Institute. 2024 116(8):1230-1237. PMID: 38539045.
• Kadan-Lottick NS, Zheng DJ, Wang M, [et al., including Bishop MW]. Patient-reported neurocognitive function in adult survivors of childhood and adolescent osteosarcoma and Ewing sarcoma. Journal of cancer survivorship : research and practice. 2023 17(4):1238-1250. PMID: 35059962.
• Oh C, Bishop MW, Cho SY, [et al.]. (18)F-FDG PET/CT in the Management of Osteosarcoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 64(6):842-851. PMID: 37201958.
• Furman WL, McCarville B, Shulkin BL, [et al., including Bishop MW]. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 40(4):335-344. PMID: 34871104.
• Chemaitilly W, Li Z, Brinkman TM, [et al., including Bishop MW]. Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. Cancer. 2022 128(3):606-614. PMID: 34643950.
• Martinez HR, Beasley GS, Goldberg JF, [et al., including Bishop MW]. Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. Children (Basel, Switzerland). 2021 8(12). PMID: 34943396.
• Whittle SB, Offer K, Roberts RD, [et al., including Bishop MW]. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatric blood & cancer. 2021 68(9):e29188. PMID: 34137164.
• Tonning Olsson I, Alberts NM, Li C, [et al., including Bishop MW]. Pain and functional outcomes in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study. Cancer. 2021 127(10):1679-1689. PMID: 33369896.
• Mascarenhas L, Ogawa C, Laetsch TW, [et al., including Bishop MW]. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer medicine. 2021 10(3):843-856. PMID: 33474828.